All Stories

  1. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma
  2. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers
  3. Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem